For example, loss of chr5q is present in >80% of the TP53-mutated myeloid malignancies in our study, compared to 58% and 38% of ovarian and esophageal adenocarcinomas, respectively, and fewer than 20% of any other tumor types. The gene discussed is TP53; the disease is neoplasm.